BioCryst Pharmaceuticals (BCRX)
(Delayed Data from NSDQ)
$6.79 USD
+0.05 (0.74%)
Updated Jun 5, 2024 04:00 PM ET
After-Market: $6.77 -0.02 (-0.29%) 7:58 PM ET
3-Hold of 5 3
F Value C Growth D Momentum D VGM
Brokerage Reports
0 items in cart
BioCryst Pharmaceuticals, Inc. [BCRX]
Reports for Purchase
Showing records 121 - 140 ( 174 total )
Company: BioCryst Pharmaceuticals, Inc.
Industry: Medical - Drugs
MORNING SUMMARY
Provider: RODMAN & RENSHAW, CO.
Company: BioCryst Pharmaceuticals, Inc.
Industry: Medical - Drugs
MORNING SUMMARY
Provider: RODMAN & RENSHAW, CO.
Company: BioCryst Pharmaceuticals, Inc.
Industry: Medical - Drugs
Presentations at ICAAC Highlight Peramivir - Gout Remains Key Driver
Provider: RODMAN & RENSHAW, CO.
Analyst: NOCHOMOVITZ Y
Company: BioCryst Pharmaceuticals, Inc.
Industry: Medical - Drugs
Presentations at ICAAC Highlight Peramivir ? Gout Remains Key Driver
Provider: RODMAN & RENSHAW, CO.
Analyst: NOCHOMOVITZ Y
Company: BioCryst Pharmaceuticals, Inc.
Industry: Medical - Drugs
Updates from Meeting with BioCryst Management at Rodman & Renshaw Conference
Provider: RODMAN & RENSHAW, CO.
Analyst: NOCHOMOVITZ Y
Company: BioCryst Pharmaceuticals, Inc.
Industry: Medical - Drugs
Updates from Meeting with BioCryst Management at Rodman & Renshaw Conference
Provider: RODMAN & RENSHAW, CO.
Analyst: NOCHOMOVITZ Y
Company: BioCryst Pharmaceuticals, Inc.
Industry: Medical - Drugs
MORNING SUMMARY
Provider: RODMAN & RENSHAW, CO.
Company: BioCryst Pharmaceuticals, Inc.
Industry: Medical - Drugs
Transformative Data Coming Up & Trading at Just $80 MM EV -Reiterating Outperform
Provider: RODMAN & RENSHAW, CO.
Analyst: NOCHOMOVITZ Y
Company: BioCryst Pharmaceuticals, Inc.
Industry: Medical - Drugs
Transformative Data Coming Up & Trading at Just $80 MM EV - Reiterating Outperform
Provider: RODMAN & RENSHAW, CO.
Analyst: NOCHOMOVITZ Y
Company: BioCryst Pharmaceuticals, Inc.
Industry: Medical - Drugs
MORNING SUMMARY
Provider: RODMAN & RENSHAW, CO.
Company: BioCryst Pharmaceuticals, Inc.
Industry: Medical - Drugs
Key Takeaways on the Gout Landscape from Our Conversation with Dr. Robert Terkeltaub
Provider: RODMAN & RENSHAW, CO.
Analyst: NOCHOMOVITZ Y
Company: BioCryst Pharmaceuticals, Inc.
Industry: Medical - Drugs
Key Takeaways on the Gout Landscape from Our Conversation with Dr. Robert Terkeltaub
Provider: RODMAN & RENSHAW, CO.
Analyst: NOCHOMOVITZ Y
Company: BioCryst Pharmaceuticals, Inc.
Industry: Medical - Drugs
MORNING SUMMARY
Provider: RODMAN & RENSHAW, CO.
Company: BioCryst Pharmaceuticals, Inc.
Industry: Medical - Drugs
Peramivir Appears to Retain Activity Against a Novel Strain of A(H1N1) Influenza
Provider: RODMAN & RENSHAW, CO.
Analyst: NOCHOMOVITZ Y
Company: BioCryst Pharmaceuticals, Inc.
Industry: Medical - Drugs
Peramivir Appears to Retain Activity Against a Novel Strain of A(H1N1) Influenza
Provider: RODMAN & RENSHAW, CO.
Analyst: NOCHOMOVITZ Y
Company: BioCryst Pharmaceuticals, Inc.
Industry: Medical - Drugs
MORNING SUMMARY
Provider: RODMAN & RENSHAW, CO.
Company: BioCryst Pharmaceuticals, Inc.
Industry: Medical - Drugs
Additional Studies Planned to Strengthen Gout Drug Safety Profile Presented at EULAR
Provider: RODMAN & RENSHAW, CO.
Analyst: NOCHOMOVITZ Y
Company: BioCryst Pharmaceuticals, Inc.
Industry: Medical - Drugs
Additional Studies Planned to Strengthen Gout Drug Safety Profile Presented at EULAR
Provider: RODMAN & RENSHAW, CO.
Analyst: NOCHOMOVITZ Y
Company: BioCryst Pharmaceuticals, Inc.
Industry: Medical - Drugs
MORNING SUMMARY
Provider: RODMAN & RENSHAW, CO.
Company: BioCryst Pharmaceuticals, Inc.
Industry: Medical - Drugs
1Q11 - PHASE 2 PROGRAM IN GOUT EXPANDS - KEY DATA CATALYST BY YE11
Provider: RODMAN & RENSHAW, CO.
Analyst: NOCHOMOVITZ Y